History

Venatorx Pharmaceuticals was founded in June 2010 by our three visionary, fearless leaders Drs. Christopher J. Burns, Daniel C. Pevear and Luigi Xerri. Fast forward to today, we have 80+ employees, three programs discovered in-house that are now clinical stage, with more in the pipeline!! Cheers to the many milestones to come as we work purposefully every day to get antibiotics and antiviral therapies into the hands of physicians to effectively treat patients. Below just a few of the highlights!

2021

Venatorx Expands Anti-Infectives Portfolio with HBV Candidate Hepatitis B Virus

Venatorx Named ‘Best Places to Work’ Fourth Year in a Row

2020

Venatorx Awarded NIH/NIAID Contract

Venatorx Named ‘Best Places to Work’ Third Year in a Row

Venatorx Partners with GARDP

2019

Venatorx Initiates Phase 3 Trial for Cefepime-Taniborbactam

Venatorx Named ‘Best Places to Work’ Second Year in a Row

Venatorx Announces Collaboration with BARDA (ASPR) and DTRA

Venatorx Founders named EY ‘Entrepreneurs of the Year

Venatorx President and CEO Named LSPA ‘CEO of the Year’

2018

Venatorx Enters Exclusive License Agreement with Everest Medicines II Limited

Venatorx Named Best Places to Work

Venatorx Receives Award from DTRA

Venatorx Receives FDA’s QIDP/Fast Track Designation for taniborbactam (VNRX-5133)

2017

Venatorx Receives Funding from CARB-X

Venatorx Raises $42M Series B Financing

2014

Venatorx Awarded NIH R01 Grant

2013

Venatorx Completes $3.5M Series A Financing

Venatorx Awarded Funding from The Wellcome Trust

Venatorx Award NIH Contract

2011

Venatorx Awarded Phase 1 SBIR Grant

2010

Venatorx Awarded NIH R01 Grant

Venatorx founded by Drs. Burns, Pevear and Xerri